Project Details
| Short title | EIK1003-001 (IMP1734-101) |
|---|---|
| Status | Active |
| Effective start/end date | 13/05/24 → 17/04/29 |
CTU: A first-in-human, Phase 1/2, open-label, multi-center, dose-escalation, dose-optimization, and dose-expansion study to evaluate the safety; tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors.
- Sabanathan, Dhanusha (Primary Chief Investigator)
- Chapman, Nicola (Clinical Trial Unit Staff)
- Martin, Lewis (Clinical Trial Unit Staff)
- TAIDI, Gina (Clinical Trial Unit Staff)
Project: Research